EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A Phase I Feasibility Trial of Tumor Treating Fields Therapy with Temozolomide and Bevacizumab in Pediatric High-Grade Glioma

Derek Hanson, Ana Aguilar-Bonilla, Avery Wright, Harshal Shah, Tara Lozy, Amy Smith

Neuro-Oncology Pediatrics · 21.07.2026

DOI: 10.1093/neuped/wuag042 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology Pediatrics, online erschienen am 21.07.2026. Verfasst von Derek Hanson und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pediatric high-grade glioma (HGG) has a poor prognosis with limited therapeutic options. Tumor Treating Fields (TTFields) therapy, delivered via Optune Gio, improves outcomes in adult glioblastoma, but pediatric data remain limited. This phase I study evaluated the safety and tolerability of TTFields combined with temozolomide and bevacizumab in pediatric HGG.

Methods

In this prospective, open-label, single-arm phase I safety study, patients aged ≥5 and ≤21 years with newly diagnosed or recurrent supratentorial high-grade glioma (HGG) received TTFields therapy (200 kHz, ≥18 hours/day) with temozolomide and bevacizumab in 28-day cycles. The primary endpoint was the occurrence of protocol-defined treatment-related dose-limiting toxicities (DLTs) during the first two cycles (56 days). Secondary endpoints included progression-free survival (PFS), overall survival (OS), and quality of life (QOL).

Results

Seven patients (ages 13–21; five newly diagnosed, two recurrent glioblastoma) were enrolled, with six evaluable for safety. No protocol-defined treatment-related DLTs occurred during the 56-day safety evaluation period. Grade 3–4 adverse events were consistent with expected chemotherapy-related toxicities. Device-related toxicities were limited to manageable dermatologic reactions. Among the four newly diagnosed evaluable patients, three progressed after Cycles 8–13, while one remained in remission >5 years from diagnosis. Both recurrent patients progressed after two cycles. QOL responses showed low device-related burden for most participants. One patient discontinued after Cycle 1 due to substantial QOL impact.

Conclusion

TTFields combined with temozolomide and bevacizumab met the protocol-defined safety threshold in pediatric HGG, with no device-related severe toxicities. These findings support further investigation of TTFields-based therapy in larger prospective studies.

Zitieren

APA

Hanson, D., Aguilar-Bonilla, A., Wright, A., Shah, H., Lozy, T., & Smith, A. (2026). A Phase I Feasibility Trial of Tumor Treating Fields Therapy with Temozolomide and Bevacizumab in Pediatric High-Grade Glioma. Neuro-Oncology Pediatrics. https://doi.org/10.1093/neuped/wuag042

Vancouver

Hanson D, Aguilar-Bonilla A, Wright A, Shah H, Lozy T, Smith A. A Phase I Feasibility Trial of Tumor Treating Fields Therapy with Temozolomide and Bevacizumab in Pediatric High-Grade Glioma. Neuro-Oncology Pediatrics. 2026. doi:10.1093/neuped/wuag042

BibTeX
@article{Hanson2026,
  author = {Hanson, Derek and Aguilar-Bonilla, Ana and Wright, Avery and Shah, Harshal and Lozy, Tara and Smith, Amy},
  title = {A Phase I Feasibility Trial of Tumor Treating Fields Therapy with Temozolomide and Bevacizumab in Pediatric High-Grade Glioma},
  journal = {Neuro-Oncology Pediatrics},
  year = {2026},
  doi = {10.1093/neuped/wuag042}
}
Kostenlos starten →